Investor Presentation Full Year 2017

Investor Presentation Full year 2017 Slide 10 VictozaⓇ continues strong growth trajectory in the US driven by GLP-1 market volume growth of 23% US GLP-1 market development MAT GLP-1 TRx volume Total TRX - Growth rate MAT volume US GLP-1 market monthly TRX US GLP-1 volume market share GLP-1 TRX - VictozaⓇ albiglutide exenatide dulaglutide (million) 10 8 16 2 Nov 2014 Source: IQVIA NPA monthly, Nov 2017 changing diabetes® growth rate volume (000) VictozaⓇ albiglutide exenatide GLP-1 TRX - dulaglutide market share 35% 400 100% 30% 350 80% 300 25% 250 20% 60% 200- 44% 15% 150 40% 10% 37% 100 20% 15% 5% 50 4% 0% 0 0% Nov Nov Nov Nov Nov 2017 2014 2017 2014 2017 novo nordisk

View entire presentation